Denali Therapeutics (DNLI) FY2023 results: revenue $331 million, up 204.7% on the year
Denali Therapeutics Inc. (DNLI) reported revenue of $331 million for fiscal 2023, the year ended 31 December 2023, up 204.7% on the year before. Net income was -$145 million, and diluted earnings per share $-1.06. The figures are the company's own, from the 10-K it filed with the SEC on 28 February 2024.
Revenue
$331 million
+204.7% on the year
FY2016FY2023
Operating margin
-59.5%
-314.2% a year earlier
FY2016FY2023
Net income
-$145 million
FY2016FY2023
Diluted EPS
-$1.06
FY2016FY2023
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2023
FY2022
FY2021
On the year
Last 8 years
Operating cash flow
-358
-245
-211
Capital expenditure
12.9
17.8
8.5
-27.4%
Free cash flow
-371
-263
-220
Free cash flow margin
-112.2%
-242.1%
-451.9%
Cash from investing
249
-141
-21.6
Cash from financing
17.8
311
19.3
-94.3%
Depreciation and amortisation
16.7
10.4
8.6
+61.1%
Share-based compensation
108
99.8
85.2
+8.3%
Diluted shares, weighted
137m
126m
122m
+9.4%
Shares outstanding at period end
138m
136m
122m
+1.8%
Balance sheet
$ million
FY2023
FY2022
FY2021
On the year
Last 8 years
Shareholders' equity
1,031
1,042
962
-1.1%
Debt
0.0
0.0
0.0
Operating lease liabilities
45.0
53.0
58.6
-15.2%
Finance lease liabilities
0.0
n/a
n/a
Other liabilities
78.0
365
383
-78.6%
Total liabilities and equity
1,154
1,460
1,404
-21.0%
Fixed assets
45.6
44.1
38.9
+3.4%
Investments
907
1,118
997
-18.8%
Cash and equivalents
127
218
293
-41.7%
Other assets
73.8
79.9
74.4
-7.7%
Total assets
1,154
1,460
1,404
-21.0%
10-K for the year ended 31 December 2023, filed 28 February 2024: the filing.